What are you talking about this time???? @Mason14 stated it was excellent achievement for CR so early in Ph1 clinical trial and then on the same post said management isn't seeing efficacy so are increasing dosage when he clearly know the purpose of Ph1 clinical trial is to demonstrate safety to determine OBD for Ph2 clinical trial to demonstrate efficacy.
He then used his own misleading ORR table when VAXINIA was clearly design for all solid cancer so some tumour might not response effectively with only CF33 and need CD19 which is the point of OASIS. Also the company he used as an example of a decade same technology used by CF33 going nowhere is currently conducting Ph3 clinical trial. Funnily, he isn't questioning RAC's only IP which is also a decade old technology and hasn't even commence Ph1 clinical trial lol. Also questioned Azer-Cel's CAR-T autologous technology as expensive when Azer-Cel technology is allogeneic so is a lot cheaper to manufacturer.
Now he has run out of these angles so is attacking CHECKvacc, I provided him a link to a medical publication which suggest CF33 did work and the clinical trial was discontinue as TBNC is covered by the VAXINIA clinical trial, do you want IMU to waste valuable fund and resource on conducting the same clinical trial????
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)